ClinicalTrials.gg
CompletedNCT04443023Compare-TAVIUpdated Apr 23, 2026

Comparison of Eligible TAVI-valves - Cohort B

An interventional study of chosen TAVI valve in Transcatheter Aortic Valve Implantation, sponsored by Aarhus University Hospital Skejby. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Aarhus University Hospital Skejby · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,031
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study performs head-to-head comparison of two TAVI-valves: Sapien and Myval.

Read the detailed description

The purpose of the present study is to ensure a continuous comparison of the TAVI-valves implanted, and to monitor long-term valve performances.

Purpose: To randomize between two TAVI-valve types in patients who according to a heart team conference is found eligible for treatment with more than one valve.

Hypotheses:

  1. There is no difference in the combined endpoint (death, stroke, moderate/severe para-valvular leakage, moderate/severe device stenosis) between the two valves to be compared.
  2. There is no difference between valves in secondary endpoints: death, stroke, moderate/major paravalvular leakage, moderate/severe aortic device stenosis, new pacemaker implantation, readmission for congestive heart failure, 6-minute walk test, and degeneration of the valve as evaluated by computerized tomography (HCT), transthoracic echocardiography (TTE), transesophageal echocardiography (TEE), or MRI.

Design: Randomized controlled trial with clinical national registry follow-up.

Centers eligible for inclusion: Scandinavian and European centers who fulfill the above mentioned criteria.

Randomization:

Before randomizing patients, the center decides which two valves the patient is found eligible for, and enters these valves in the electronic randomization form (TrialPartner). Randomization is then performed between these two valves. A patient is only randomized if a dedicated technical TAVI conference has found the patient eligible for treatment with both valves.

Consecutive cohorts are established.

In the current study we plan to initiate the following cohorts:

Cohort B: Patients randomized to the Sapien or the Myval TAVI valve.

Operator requirements:

Any procedure requires that the physician has performed at least 15 implantations with the valve in use. Otherwise the procedure is performed according to the routine of the institution.

02

Conditions studied

  • Transcatheter Aortic Valve Implantation
03

In context

Lead sponsor

Aarhus University Hospital Skejby is the lead sponsor of 60 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient more than 18 years of age.
  2. Patient eligible for at least 2 valves being implanted routinely at the participating center, according to a TAVI heart team conference.
  3. The center experience for each of the valves considered should be more than 15 cases a year, and at least 15 valves implanted before a valve can be used in the trial.
  4. The center volume should be more than 75 cases a year.
  5. The patient has given signed .
  6. TAVI performed via the femoral artery.

Exclusion criteria

Exclusion Criteria:

1. Not able to give written inform consent

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,031 participants (actual)

Study arms

  • Active comparator
    Sapien

    Patients randomized to treatment

    Device: chosen TAVI valve

  • Active comparator
    Myval

    Patients randomized to treatment

    Device: chosen TAVI valve

Interventions

  • Devicechosen TAVI valve

    chosen TAVI valve

06

What researchers measure

Primary outcomes

  1. Percentage of patients with MACE (Major Adverse Cardiovascular Events)

    Mortality, stroke, moderate/major PVL, moderate/severe aortic device stenosis at 1 year, using VARC-3 criteria

    Time frame: 1 year

Secondary outcomes

  1. Percentage of patients with MACE

    Mortality, stroke, moderate/major paravalvular leakage (PVL), moderate/severe aortic device stenosis at 1 year, using VARC-3 criteria

    Time frame: 30 day, 3-year, 5-year and 10-year

  2. Percentage death

    Mortality

    Time frame: 30-day, 1-year, 3-year, 5-year, 10-year

  3. Percentage of patients with stroke

    According to Valve Academic Research Consortium (VARC)-3 criteria

    Time frame: During admission, 30-day, 1-year, 3-year, 5-year, 10-year

  4. Percentage of patients with moderate or severe paravalvular leakage

    Moderate or severe paravalvular leakage according to VARC-3 criteria

    Time frame: 30-day, 1-year, 3-year, 5-year, 10-year

  5. Percentage of patients with moderate/major aortic stenosis

    According to VARC-3 criteria

    Time frame: 30-day, 1-year, 3-year, 5-year, 10-year

  6. Percentage of patients with new pacemaker

    New Pacemaker after TAVI-procedure

    Time frame: During admission, 30-day, 1-year, 3-year, 5-year, 10-year

  7. Percentage of patients with major bleeding

    Major bleeding according to Bleeding Academic Research Consortium (BARC) type 3 or 5 criteria, resulting in either a drop in Hbg\>=1.86 mmol/l or \>=2 units of blood transfusion

    Time frame: 30-day, 1-year, 3-year, 5-year, 10-year

  8. Distance in meters during 6-minute walk test

    6-minute walk test

    Time frame: 30-day, 1-year, 3-year, 5-year, 10-year

  9. Percentage of patients with other TAVI-related complications

    conversion to open surgery during implantation, unplanned use of cardiopulmonary support (CPS), coronary artery obstruction, ventricular septal perforation, mitral valve apparatus damage or dysfunction, cardiac tamponade, valve thrombosis, valve embolization, valve migration, need for TAVI-in-TAVI deployment, using VARC-3 criteria

    Time frame: During TAVI-procedure

  10. Percentage of patients with endocarditis

    Endocarditis

    Time frame: 30-day, 1-year, 3-year, 5-year, 10-year

  11. Proportion with successful implantation of the chosen valve.

    This means no need for more than 1 TAVI valve, no change to another valve than planned during the procedure because it was impossible to implant the valve planned, and no conversion to surgery or procedure-related death.

    Time frame: During procedure

  12. Percentage of patients with major vascular access site and access-related complications

    According to VARC-3 criteria

    Time frame: During admission and 30-day

  13. Percentage of patients with valve thrombosis or severe stenosis

    Valve thrombosis or severe stenosis confirmed by Echo or HCT

    Time frame: 30-day, 1-year, 3-year, 5-year, 10-year

  14. Percentage of patients with readmission with congestive heart failure

    Readmission with congestive heart failure

    Time frame: 30-day, 1-year, 3-year, 5-year, 10-year

  15. Percentage of patients with increase in creatinin level of 100% or more, or dialysis

    Increase in renal creatinine level more than to \>=200% (AKIN stage 2-3, VARC-3 criteria) or dialysis

    Time frame: during admission and within 30 days

  16. Percentage of patients with moderate/severe PVL stratified according to level of annular calcium on HCT in three groups

    Severity of PVL stratified according to level of annular calcium on HCT (low/medium/high)

    Time frame: 30-day

  17. Mean Gradient (AO) stratified according to level of annular calcium on HCT in three groups

    Gradient (AO) stratified according to level of annular calcium on HCT (low/medium/high)

    Time frame: 30-day

  18. Percentage of patients with prosthesis-patient mismatch

    Prosthesis-patient mismatch (EOA/body surface area). Severe PPM≤0.65 cm2/m2. Moderate PPM≤0.85 cm2/m2 according to VARC-3 criteria

    Time frame: 30-day, 1-year, 3-year, 5-year, 10-year

  19. Mean effective orifice area measured by MRI

    Effective orifice area measured by MRI in patients participating in MRI-substudy

    Time frame: 30-day

  20. Percentage of patients with leaflet thickening (hypoattenuated leaflet thickening = HALT) or reduced leaflet motion or thrombus assessed by HCT

    Leaflet thickening (hypoattenuated leaflet thickening = HALT) or reduced leaflet motion or thrombus assessed by HCT in patients participating in HCT-substudy

    Time frame: 30-day and 1-year

  21. Mean volume of aortic regurgitation measured by MRI

    Volume of aortic regurgitation measured by MRI in patients participating in MRI-substudy

    Time frame: 30-day

  22. Other tavi-related complications

    Anulus rupture or aortic rupture

    Time frame: 30-day

  23. AMI

    Acute Myocardial Infarction

    Time frame: 30-day, 1-year, 3-year, 5-year and 10-year

  24. PCI og CABG

    Percutaneous Coronary Intervention or coronary artery bypass grafting

    Time frame: 30-day, 1-year, 3-year, 5-year and 10-year

  25. Reopeation

    Reopeation with TAVI, Surgical ortic valve replacement (SAVR) or BAV (Balloon aortic valvuloplasty) according to VARC-3 criteria

    Time frame: 30-day, 1-year, 3-year, 5-year and 10-year

  26. Afib

    Newly diagnosed atrial fibrillation according to VARC-3 criteria

    Time frame: 30-day, 1-year, 3-year, 5-year and 10-year.

07

Study locations

1 site
  • Aarhus University Hospital
    Aarhus, 8200, Denmark
08

References and documents

Publications

  • Terkelsen CJ, Thim T, Freeman P, Dahl JS, Norgaard BL, Kim WY, Tang M, Sorensen HT, Christiansen EH, Nissen H. Randomized comparison of TAVI valves: The Compare-TAVI trial. Am Heart J. 2024 Aug;274:84-94. doi: 10.1016/j.ahj.2024.05.003. Epub 2024 May 9. PubMed 38729550 ↗
  • Thim T, Nissen H, Freeman P, Sanchez Dahl J, Christiansen EH, Eftekhari A, Linde Norgaard B, Povlsen JA, Poulsen SH, Jensen RV, Ovrehus KA, Terkelsen CJ. Transcatheter aortic valve implantation outcomes by patient age and sex in COMPARE-TAVI 1: a cohort study. BMJ Open. 2026 Jul 10;16(7):e121596. doi: 10.1136/bmjopen-2026-121596. PubMed 42431661 ↗
  • Terkelsen CJ, Freeman P, Dahl JS, Thim T, Norgaard BL, Mogensen NSB, Tang M, Eftekhari A, Povlsen JA, Poulsen SH, Pedersen L, Hjort J, Ellert J, Christiansen EH, Sorensen HT, Nissen H. SAPIEN 3 versus Myval transcatheter heart valves for transcatheter aortic valve implantation (COMPARE-TAVI 1): a multicentre, randomised, non-inferiority trial. Lancet. 2025 Apr 19;405(10487):1362-1372. doi: 10.1016/S0140-6736(25)00106-0. Epub 2025 Apr 2. PubMed 40187364 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Normally this will be possible when data are published and anonymized. Mainly to support meta-analysis on individual level data.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When endpoints are published in an international peer-reviewed paper

Access criteria: To share data there shall be a well-defined purpose. This could be to contribute to a meta-analysis on individual level data.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Nov 2023, 40 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2020
First posted
Jun 23, 2020
StartActual
Jun 15, 2020
Primary completionActual
Nov 2, 2023
CompletionActual
Nov 2, 2025
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04443023
Lead sponsor
Aarhus University Hospital Skejby
Responsible party
Christian Juhl Terkelsen (Principal investigator, Aarhus University Hospital Skejby) — Principal investigator
First posted
Jun 23, 2020
Start date
Jun 15, 2020
Primary completion
Nov 2, 2023
Completion
Nov 2, 2025
Last update
Apr 23, 2026

Study contacts

henrik nissen, PhD
study chair · odense univeristy hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion